← boardnext 2027-06-30
INDP
Indaptus Therapeutics, Incdistress 9/10 · high distress / dilution risk$2.78+5%today-78% from 52w high
Lead: Solid Tumor
Revenue
pre-revenue
Liquidity
$8M
Runway
0.5 yrs
Shares 1y
+10134%
Price & events
-1.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
+5.1%
1D
+9.9%
1W
-25.1%
1M
-11.7%
3M
+2.6%
6M
-73.4%
1Y
-95.3%
2Y
-99.3%
5Y
-99.3%
All
Overview
- Market Cap
- $314.81M
- Volume
- 24.82K
- 52 Week Range
- $1.06 – $12.58
- Total Shares
- 113.24M
- Float Shares
- 3.24M
- Short %
- 0.10%
- % Held by Insiders
- 96.93%
- % Held by Institutions
- 0.08%
- RVOL
- 0.07x
- Beta
- 1.14
Pipeline stages · 1 programs
Decoy20, Tislelizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-06-30 Estimated 50% readout ~2027-08-14 | Phase 1/2 | Decoy20, Tislelizumab | Solid Tumor, Adult, HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer), Pancreatic Adenocarcinoma, NSCLC Non-small Cell Lung Cancer, Squamous Cell Cancer of the Head and Neck, UC (Urothelial Cancer), MSI-H Cancer | — | active not recruiting |
Catalyst news & presentations · 3
- 2025trial initiationsecondaryDecoy20 · Combination study of Decoy20 with tislelizumabSEC 8-K
- 2025-06-30partnershipClosed $3.4M second tranche of private placement of convertible notes and warrants, total $5.7M raised.SEC 8-K
- 2024-10-17partnershipDecoy20 · Clinical supply agreement with BeiGene for combination studySEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2024-11-13Maxim GroupBuy
- 2024-10-16HC Wainwright & Co.Buy
Competitors — Solid Tumor
- NVSEFNOVARTIS AG$292.0B · D3
- BEIGFBeOne Medicines Ltd.$31.7B · D1
- INCYINCYTE CORP$23.1B · D0
- ERASErasca, Inc.$5.9B · D4
- CELG-RIBRISTOL MYERS SQUIBB CO$241M · D2
- CRBPCorbus Pharmaceuticals Holdings, Inc.$164M · D7
- BCYCBICYCLE THERAPEUTICS PLC$124M · D4
- XLOXilio Therapeutics, Inc.$50M · D1
- APREAprea Therapeutics, Inc.$8M · D6
Recent news
- 2026-07-20Indaptus Therapeutics, Inc. SEC Filing (Jul 20, 2026) - Stock Titan
- 2026-07-19Signal Proxy Intelligence Recommends Full Support for All Three Items at Indaptus Therapeutics, Inc. Annual Meeting - apg-wi.com
- 2026-07-19Signal Proxy Intelligence Recommends Full Support for All Three Items at Indaptus Therapeutics, Inc. Annual Meeting - WBOC TV
- 2026-07-16Indaptus Therapeutics (NASDAQ: INDP) seeks approval for 2026 equity plan - Stock Titan
- 2026-07-16Indaptus Therapeutics (INDP) Proxy filing Summary - Quartr
- 2026-07-08Insider Traders Lose US$34k As Indaptus Therapeutics Drops - simplywall.st
- 2026-07-08Insider Traders Lose US$34k As Indaptus Therapeutics Drops - Sahm
- 2026-07-07INDP Q4 2025 Earnings: Wider-than-Expected Loss as Stock Declines Nearly 6% - Revenue Estimate Trend - dars.gov.et
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.